Key Takeaways
BriaCell Therapeutics Corp. (BCTX) received Food and Drug Administration (FDA) clearance to begin a Phase 1/2a clinical trial for Bria-BRES+, its next-generation immunotherapy for metastatic breast cancer, sending shares up more than 5% on the news.
"The unique design of Bria-BRES+ offers the potential for a favorable safety profile and meaningful therapeutic benefit in metastatic breast cancer," Dr. William V. Williams, BriaCell’s President & CEO, said in a statement. "We look forward to advancing Bria-BRES+ into the clinic as we seek to bring new hope to these patients who have few to no effective treatment options.”
The clearance of the Investigational New Drug (IND) application allows BriaCell to move its second personalized immunotherapy into human trials. The company confirmed that clinical supplies are prepared, with plans to begin dosing patients in the coming months. According to preclinical data presented at the American Association for Cancer Research (AACR), Bria-BRES+ activates the immune system through multiple pathways, including T-cells, dendritic cells, and natural killer (NK) cells.
This trial moves a key asset for the $29.5 million market cap company into the clinic, building on its existing Bria-IMT and Bria-OTS platforms. The new therapy’s broader immune activation is designed to improve upon results seen in earlier programs, such as the complete resolution of a lung metastasis in one Bria-OTS patient. That single-patient event previously drove the stock up 42.9% in a single day, and investors will be watching for Bria-BRES+ to replicate such outcomes in a larger population.
BriaCell's announcement highlights the case of a 78-year-old woman with advanced metastatic breast cancer who had failed multiple previous treatments. After four doses of BriaCell's first-generation Bria-OTS therapy, the patient experienced a 100% resolution of a lung metastasis. The response was first seen at the two-month mark and was confirmed through 11 months of follow-up, providing a clinical proof-of-concept that the company hopes to build on.
Bria-BRES+ is an "off-the-shelf" cell-based immunotherapy that includes additional components intended to enhance the immune response compared to Bria-OTS. By activating both the adaptive and innate immune systems, the company believes the therapy may produce more durable responses and prevent cancer cells from evading the immune attack.
The market responded positively to the FDA clearance, with BriaCell’s stock climbing 5.65% to $4.30 in morning trade, adding approximately $2 million to its valuation. The move is notable as it appears stock-specific, with peer biotech stocks showing mixed performance.
However, the stock remains volatile and trades significantly below its 200-day moving average of $7.37 and its 52-week high of $39.50. BriaCell has a history of sharp price movements in response to clinical news. While a January 13 update on the Bria-OTS patient's lung metastasis resolution caused a 42.9% rally, other positive data presentations at major medical conferences in April resulted in more muted or even negative stock reactions, highlighting investor sensitivity to the specifics of clinical data in the early-stage biotech sector.
With the IND cleared, the next major catalyst for BriaCell will be the initiation of patient dosing in the Phase 1/2a study, which the company projects will occur in the coming months. Following that, investors will anticipate initial safety and efficacy data from the trial to see if the multi-arm immune activation shown in preclinical studies translates into meaningful clinical benefit for patients with metastatic breast cancer.
What did BriaCell (BCTX) announce about Bria-BRES+ on May 6, 2026?
BriaCell announced FDA clearance to begin a Phase 1/2a IND study of Bria-BRES+ in metastatic breast cancer. According to the company, clinical supplies are prepared and dosing is planned in the coming months.
When will BriaCell (BCTX) start the Phase 1/2a study of Bria-BRES+?
The company plans to initiate the Phase 1/2a study in the coming months. According to BriaCell, clinical supplies are already prepared to support initial dosing timelines.
What preclinical immune activity did BriaCell report for Bria-BRES+ (BCTX)?
BriaCell reported Bria-BRES+ activated both adaptive and innate immunity, including naïve T cells, dendritic cells, and NK cells. According to the company, these signals appeared in their AACR preclinical poster data.
How strong is the clinical evidence cited by BriaCell (BCTX) for Bria-BRES+?
Evidence cited is preclinical activation data plus a single-patient clinical observation of a lung metastasis resolution. According to BriaCell, the clinical observation was confirmed at multiple follow-ups but is not broad clinical proof.
What is Bria-BRES+ and how does it differ from Bria-OTS (BCTX)?
Bria-BRES+ is described as a next-generation, personalized, off-the-shelf cell-based immunotherapy with additional immune-activating components. According to BriaCell, it builds on Bria-OTS by aiming for broader immune activation.
This article is for informational purposes only and does not constitute investment advice.
